Please login to the form below

Not currently logged in
Email:
Password:

DLBCL

This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.

Roche’s Polivy receives EC approval for lymphoma therapy

Roche’s Polivy receives EC approval for lymphoma therapy

The study involved those with previously untreated DLBCL and all patients were followed for at least two years. ... Treatment with this regimen has been shown to reduce the chance of relapse and therefore need for subsequent treatments, limiting the

Latest news

More from news
Approximately 9 fully matching, plus 64 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party

  • Deal Watch January 2018

    The company switched focus to its JCAR017 programme and recently reported promising data in a pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....